Depression, selective serotonin reuptake inhibitors, and osteoporosis.
An increasing number of studies suggest an association between depression and osteoporosis. In a mouse model, depression induces bone loss, mediated by brain-to-bone sympathetic signaling. Depression and bone antianabolic sympathetic tone are alleviated by increasing central serotonin (5-hydroxytryptamine, 5-HT) levels. However, selective serotonin reuptake inhibitors (SSRIs), the first-line antidepressants, increase extracellular 5-HT levels but have deleterious skeletal effects. The skeletal serotonergic system consists of 5-HT receptors and the 5-HT transporter (5-HTT) in osteoblasts and osteocytes. 5-HTT is a transmembrane protein targeted by SSRIs. 5-HT restrains osteoblastic activity, thus leading to bone loss. Apparently, the negative skeletal effects of the peripheral SSRI-induced increase in 5-HT outweighs the skeletal benefits resulting from the enhanced central 5-HT antidepressant and antisympathetic activity. Overall, major depression appears as an important risk factor for osteoporosis. However, antidepressants, mainly SSRIs, should be evaluated in view of the causal relationship between depression and bone loss, and vis-à-vis their skeletal adverse effects. Patients with depressive disorders should undergo a routine skeletal evaluation and receive timely antiosteoporotic therapy, especially when SSRI treatment is prescribed.
Bab
Itai
I
The Hebrew University of Jerusalem, Israel. babi@cc.huji.ac.il
Yirmiya
Raz
R
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects; D015984:Causality; D015897:Comorbidity; D003863:Depression / Q000175:diagnosis / Q000453:epidemiology* / Q000503:physiopathology; D006801:Humans; D010024:Osteoporosis / Q000453:epidemiology* / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000453:epidemiology / Q000503:physiopathology; D017698:Postmenopause / Q000502:physiology; D017697:Premenopause / Q000502:physiology; D011985:Receptors, Serotonin / Q000502:physiology; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use
D011985:Receptors, Serotonin; D017367:Selective Serotonin Reuptake Inhibitors
Cell. 2009 Sep 4;138(5):976-89
19737523
Horm Metab Res. 2010 Jun;42(7):467-82
20455194
Nutr Rev. 2007 Dec;65(12 Pt 2):S147-51
18240539
Alcohol Res Health. 2001;25(4):276-81
11910705
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):529-37
11999904
Lancet. 2001 Dec 15;358(9298):2061-8
11755632
J Clin Invest. 1998 Jul 15;102(2):274-82
9664068
Am J Epidemiol. 2006 Mar 1;163(5):421-32
16394201
Curr Top Med Chem. 2002 Jun;2(6):507-28
12052191
J Neurochem. 2008 Sep;106(6):2322-36
18643796
Thromb Res. 1999 Jul 1;95(1):1-18
10403682
Maturitas. 2007 Jan 20;56(1):1-11
16806750
Hormones (Athens). 2006 Jan-Mar;5(1):9-16
16728381
J Biol Chem. 2003 Oct 31;278(44):43146-56
12939279
Biol Psychiatry. 2009 Sep 1;66(5):423-32
19446797
Nature. 1951 Sep 1;168(4270):385
14875097
Curr Osteoporos Rep. 2006 Dec;4(4):134-9
17112423
Alcohol Clin Exp Res. 2005 Dec;29(12):2077-90
16385177
Mol Psychiatry. 2008 Jul;13(7):717-28
17700577
Arch Pediatr Adolesc Med. 2008 Dec;162(12):1181-8
19047547
Toxicol Appl Pharmacol. 2007 May 15;221(1):111-8
17383703
J Clin Endocrinol Metab. 2007 Feb;92(2):497-503
17077132
Mol Cell Endocrinol. 2005 Oct 20;242(1-2):1-9
16085354
J Pharmacol Exp Ther. 2008 Nov;327(2):316-23
18708586
Nat Med. 2010 Mar;16(3):308-12
20139991
J Cell Biochem. 2006 Apr 15;97(6):1283-91
16329113
Cell Metab. 2006 Nov;4(5):341-8
17084709
Bone. 2006 Dec;39(6):1313-21
16884969
J Clin Psychopharmacol. 2008 Aug;28(4):411-7
18626268
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12956-61
16126903
Thorax. 1999 Feb;54(2):161-8
10325923
Cell. 2008 Nov 28;135(5):825-37
19041748
Curr Opin Pharmacol. 2007 Dec;7(6):648-52
18032111
Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16876-81
17075068
Inflamm Allergy Drug Targets. 2008 Mar;7(1):19-23
18473896
Addict Behav. 2006 Jan;31(1):133-6
15922514
FASEB J. 2008 Feb;22(2):418-27
17846081
Endocr Rev. 2002 Jun;23(3):279-302
12050121
Am J Physiol. 1994 Jan;266(1 Pt 1):L46-52
8304469
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13960-5
11717453
J Neurosci. 1996 Apr 1;16(7):2352-64
8601815
FASEB J. 2008 Jan;22(1):285-94
17704191
Arch Biochem Biophys. 2008 May 15;473(2):231-6
18410742
Osteoporos Int. 2009 Aug;20(8):1309-20
19343469
Osteoporos Int. 2002 Dec;13(12):932-6
12459935
Pharmacol Ther. 2001 Nov-Dec;92(2-3):179-212
11916537
Lancet. 1997 May 24;349(9064):1498-504
9167458